Pharma and medical imaging company MedTrace announced the appointment of Nicholas Borys, M.D., as Chief Medical Officer (CMO). Dr. Borys is a skilled and experienced healthcare executive with over 25 years experience in advancing portfolios of novel therapies across diverse indications in cardiovascular, cancer, and central nervous system disease. Among his accomplishments, he led drug development at IMUNON, Amersham, and Hoffmann-La Roche, and successfully led and completed four new drug applications. “Nick brings in-depth knowledge to MedTrace and will play a significant role in accelerating our Phase III Trial. I am incredibly pleased to have him join MedTrace and our executive management team”, CEO Ann Kristin Led says.
Nicholas Borys, MD, CMO at MedTrace has extensive global experience in leading clinical research and drug development programs for innovative therapies and diagnostics in cardiology, oncology, neurology, and nuclear medicine. He has spent 15 years as Executive Vice President and CMO at the Nasdaq-listed pharma company IMUNON and now joins MedTrace after having spent the last two years as a Consulting Chief Medical Officer at NB&C Consulting. At MedTrace he will be responsible for the successful completion of the company’s Phase III Clinical Trial.
“Nicholas Borys is a significant addition to our team, bringing an impressive track record and an extensive network that will help us further accelerate our trial site activation. We are pleased and proud to have him on board. With his expertise, our executive management team now has the strongest possible foundation to address the U.S. market, speed up our trial, and secure the necessary regulatory approvals ahead of a full market launch,” says CEO Ann Kristin Led.
As Chief Medical Officer at MedTrace, Nicholas Borys will lead the company’s Clinical, Regulatory, and Medical Affairs departments. Commenting on his new position, he said:
“Joining MedTrace, an advanced medical imaging company, has brought my career to a full circle where I can bring my experience in drug development, nuclear medicine and therapeutics together. MedTrace has developed a new generation of imaging technology that captures and precisely measures blood flow and perfusion anywhere in the body. This 15O-water point-of-care solution has the potential to completely transform the way medical imaging is performed today and helping direct optimal care of patients in the future. Currently, MedTrace is focused on cardiology, but the potential of this innovation extends into oncology and neurology, among other fields. I am thrilled to join the team bringing MedTrace’s advanced technology to the market.”
MedTrace’s Phase III Clinical Trial, Rapid Water Flow, is designed to evaluate the diagnostic accuracy and safety of 15O-water as a myocardial perfusion (Positron Emission Tomography) PET imaging agent. The approximately 182-patient trial is progressing according to the development plan and roughly one-fourth of patients have been enrolled across eight major university hospitals in Europe and North America. Read more about the trial here.
Source: medtracepharma.com
One of the most compelling acquisition sagas in the pharma industry in recent times has come to an end, with Pfizer prevailing over Novo Nordisk in a fierce bidding war to acquire obesity biotech Metsera. After mulling over competing offers from both Pfizer and Novo Nordisk, Metsera has decided to go with the former’s $10bn offer.
French industrial group Anjac Health & Beauty has acquired food supplements supplier PharmaLinea and now comprises 17 complementary companies with R&D and production capacities in health, beauty, personal care, and food supplements.
The big pharma company will pay $221.50 per share in cash to buy Cidara, a US biotech that has developed a platform of drug-Fc conjugates (DFCs). The technology has allowed Cidara to build molecules with prolonged half-life whose efficacy does not require an immune response.
